Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Papaverine is an opium alkaloid used clinically as a direct smooth muscle relaxant. Its primary molecular target is phosphodiesterase enzymes (notably PDE10A), whose inhibition increases intracellular levels of cAMP and cGMP, disrupting pathways required for sustained muscle contraction. Papaverine also blocks calcium ion channels, further decreasing calcium-dependent contractility. These mechanisms allow papaverine to treat vascular, visceral, and urological spasms. Although it is not structurally related to other opium alkaloids, its unique effects on smooth muscle contraction underpin its clinical utility. Some studies suggest papaverine can affect mitochondrial respiration, offering a secondary route for muscle relaxation in certain tissues.
Inhibition of phosphodiesterase (especially PDE10A), resulting in increased intracellular cAMP and cGMP levels, causing smooth muscle relaxation. Blockade of calcium ion channels, reducing calcium influx and release, thereby further decreasing contraction. Inhibition of mitochondrial respiration (secondary mechanism in some tissues).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase (particularly PDE10A) (PDE (or PDE10A for specificity)).